Ensemble Discovery Corporation And Roche Initiate Product Development Program to Advance New Diagnostic Technology to Optimize Cancer Therapy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ensemble Discovery Corp today announced the extension of its collaboration with Roche to apply its proprietary diagnostic technology to personalized cancer therapy. The collaboration will deploy Ensemble Discovery’s proprietary diagnostic assays (based upon DNA-Programmed ChemistryTM) in human clinical studies to analyze combinations of Epidermal Growth Factor Receptors (EGFR) present in cancer tissues. This family of receptors is one of the most actively targeted in modern oncology therapy. The goal of the project is to develop product prototypes that detect EGFR receptor dimers (protein complexes made up of two identical molecules) in human cancer tissue samples and ultimately to use those products to improve the management of cancer patients and their therapy.